000 | 01514 a2200325 4500 | ||
---|---|---|---|
005 | 20250517033201.0 | ||
264 | 0 | _c20160217 | |
008 | 201602s 0 0 eng d | ||
022 | _a1548-8756 | ||
024 | 7 |
_a10.14694/EdBook_AM.2015.35.76 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPostow, Michael A | |
245 | 0 | 0 |
_aManaging immune checkpoint-blocking antibody side effects. _h[electronic resource] |
260 |
_bAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting _c2015 |
||
300 |
_a76-83 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
650 | 0 | 4 |
_aCTLA-4 Antigen _xantagonists & inhibitors |
650 | 0 | 4 |
_aChemical and Drug Induced Liver Injury _xdrug therapy |
650 | 0 | 4 |
_aColitis _xchemically induced |
650 | 0 | 4 |
_aDiarrhea _xchemically induced |
650 | 0 | 4 |
_aGranulocyte-Macrophage Colony-Stimulating Factor _xtherapeutic use |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aOpportunistic Infections _xdrug therapy |
650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
773 | 0 |
_tAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting _gp. 76-83 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.14694/EdBook_AM.2015.35.76 _zAvailable from publisher's website |
999 |
_c24919021 _d24919021 |